Business class action lawsuit

Rosen Law Firm Sues UniQure Over FDA Approval

Analysis based on 50 articles · First reported Feb 11, 2026 · Last updated Mar 08, 2026

Sentiment

-20

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The market is negatively impacted by the uncertainty surrounding UniQure's drug development and regulatory compliance, leading to potential stock price decline for UniQure. The lawsuit highlights risks for investors in the biotechnology sector regarding transparency and regulatory adherence.

Biotechnology Legal Services

Event Summary

Rosen Law Firm has announced a class action lawsuit against UniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that UniQure misrepresented and failed to disclose that the design of its Pivotal Study for a Huntington's Disease drug candidate, including comparison to the ENROLL-HD data set, was not fully approved by the United States===Food and Drug Administration. Furthermore, UniQure is accused of downplaying the likelihood of delays in its Biologics License Application timeline, despite purportedly successful study results, necessitating additional studies. Investors are encouraged to join the class action by April 13, 2026, to potentially recover damages.

Key Actions

100 Rosen Law Firm filed class action lawsuit UniQure

95 UniQure allegedly misrepresented study approval and BLA timeline

90 UniQure allegedly misrepresented and failed to disclose information

Entities Involved

stock

UniQure

UniQure is facing a class action lawsuit for allegedly misrepresenting and failing to disclose crucial information regarding the FDA approval status of its Pivotal Study design and the likelihood of delays in its Biologics License Application timeline. This could lead to significant financial penalties and reputational damage for UniQure.

Importance 100 Sentiment -50

priv

Rosen Law Firm

Rosen Law Firm is initiating and representing investors in the class action lawsuit against UniQure. This event enhances their reputation as a leading investor rights law firm and could result in substantial legal fees if the lawsuit is successful.

Importance 90 Sentiment 60

govactor

United States===Food and Drug Administration

The United States===Food and Drug Administration's alleged lack of full approval for UniQure's Pivotal Study design is central to the class action lawsuit. Their regulatory oversight is a key factor in the claims of misrepresentation against UniQure.

Importance 70 Sentiment 0

per

Philip Kim

Philip Kim, an attorney at Rosen Law Firm, is actively involved in the UniQure class action, serving as a contact for investors. His involvement highlights his role in investor rights litigation.

Importance 40 Sentiment 50

per

Lawrence Rosen

Lawrence Rosen, founding partner of Rosen Law Firm, is mentioned as a key figure in the firm's success in securities class actions. His leadership underpins the firm's efforts in the UniQure lawsuit.

Importance 40 Sentiment 50

Relationships

Philip Kim related ↔ Rosen Law Firm

Lawrence Rosen related ↔ Rosen Law Firm

United States===Food and Drug Administration related ↔ UniQure

UniQure related ↔ Rosen Law Firm

Rosen Law Firm related ↔ United States===Food and Drug Administration

UniQure related ↔ United States===Food and Drug Administration

Rosen Law Firm related ↔ UniQure

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard